Loading
Cardiac Valve Diseases and Treatments / Congenital Heart Disease Studies / Pulmonary Hypertension Research and Treatments · Journal article
Critical Pathways in Cardiology a Journal of Evidence-based Medicine · September 2, 2026
A consensus or society position rather than new primary data.
This is a narrative review that consolidates contemporary evidence on tricuspid regurgitation evaluation and management, emphasizing a paradigm shift toward earlier intervention and expanded transcatheter treatment options. The review provides expert guidance on key decision-making factors including hemodynamics, chamber remodeling, and surgical risk, but presents no new primary data and does not quantify treatment efficacy or comparative outcomes.
Narrative review. Patients with tricuspid regurgitation across the disease spectrum, with particular emphasis on severe disease and secondary mechanisms..
Clinically significant TR is associated with right ventricular failure, hepatic congestion, recurrent hospitalization, and increased mortality, contrasting with prior assumptions that mild-to-moderate TR was benign. Management has shifted toward earlier recognition and intervention; echocardiography remains central to diagnosis and procedural planning. Transcatheter edge-to-edge repair, annuloplasty systems, and transcatheter valve replacement have significantly expanded treatment options, particularly for high surgical risk patients.
Clinically significant TR is associated with right ventricular failure, hepatic congestion, recurrent hospitalization, and increased mortality, contrasting with prior assumptions that mild-to-moderate TR was benign.
Clinicians should recognize that clinically significant TR carries substantial prognostic weight and warrants earlier intervention; therapeutic choice should be individualized based on pulmonary artery pressure, RV-pulmonary artery coupling, chamber remodeling, surgical risk, and anatomic suitability. This review signals that transcatheter options have expanded the treatment landscape beyond surgery for high-risk patients.
A comprehensive narrative review synthesizing current literature on TR evaluation and management strategies, presenting expert consensus on classification, imaging, risk stratification, and therapeutic options without new primary data.
As stated by the source record.
Clinicians should recognize that clinically significant TR carries substantial prognostic weight and warrants earlier intervention; therapeutic choice should be individualized based on pulmonary artery pressure, RV-pulmonary artery coupling, chamber remodeling, surgical risk, and anatomic suitability. This review signals that transcatheter options have expanded the treatment landscape beyond surgery for high-risk patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: Tricuspid regurgitation (TR) is a common but historically under-recognized valvular heart disease. Although mild to moderate TR was long considered benign, accumulating evidence indicates that clinically significant TR is associated with right ventricular failure, hepatic congestion, recurrent hospitalization, and increased mortality. AIMS: This review aims to provide a comprehensive overview of contemporary evaluation and management strategies for TR across its clinically relevant spectrum, with particular emphasis on severe disease and secondary mechanisms when discussing intervention. METHODS: Current literature was synthesized with a focus on TR classification, underlying mechanisms, imaging and hemodynamic assessment, risk stratification, device-related TR, and evolving therapeutic strategies, including both surgical and transcatheter approaches. RESULTS: Management paradigms have shifted toward earlier recognition and intervention, with echocardiography remaining central to diagnosis and procedural planning. While medical therapy is primarily supportive, advances in transcatheter edge-to-edge repair, annuloplasty systems, and transcatheter valve replacement have significantly expanded treatment options, particularly for patients at high surgical risk. Key determinants of therapeutic decision-making include pulmonary artery pressure, right ventricle-pulmonary artery coupling, right-sided chamber remodeling, surgical risk, and anatomic suitability. CONCLUSION: TR represents a complex and rapidly evolving area of cardiology that requires individualized assessment based on anatomy, hemodynamics, comorbidities, and the quality of available evidence. Ongoing clinical trials and emerging therapies are expected to further refine treatment algorithms and future guideline recommendations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.